London, Nov 7 (IANS) Danish pharma giant Novo Nordisk has said it is aware of at least 10 deaths and 100 hospitalisations linked to compounded versions of semaglutide — the active ingredient in popular diabetes and obesity drugs Ozempic and Wegovy.
The company’s chief financial officer Karsten Munk Knudsen said that the deaths and hospitalisations, recorded in the last two years, were reported in the US Food and Drug Administration’s (FDA) adverse event reporting database for semaglutide.
While the reports are submitted by doctors, patients, drugmakers, and others, they often lack key details. These also do not establish the cause of death.
According to the US FDA, a drug may be compounded for a patient in cases where a patient with an allergy to a certain dye needs a separate medication, or people who cannot swallow a tablet or capsule.
Such drugs are also made by copying the brand-name medicines that are in short supply. The drugs are typically made by combining, mixing, or altering the ingredients to meet demand.
However, these drugs are not FDA-approved.
Amid strict regulations in the US, it was puzzling that people in the country “could inject themselves with a product that was not regulated, approved or inspected,” CEO Lars Fruergaard Jorgensen, told the media.
Besides semaglutide, the company had been looking at other compounded products and identified multiple safety concerns as well as the reports of hospitalisations and deaths, Knudsen also told the media briefing.
This was reported to the FDA by the company. In October, it also asked the FDA to ban compounding pharmacies from making copycat versions of Wegovy and Ozempic, which it said were too complex for those manufacturers to produce safely.
Meanwhile, Novo Nordisk shares jumped 8 per cent after Wegovy sales beat expectations. Sales of Wegovy were 79 per cent higher in the third quarter of 2024 compared to the same period last year, the company said.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
